The global high potency APIs market is projected to reach USD 42.59 billion by 2028, growing at a CAGR of 9.2%. Growing demand for oncology drugs, increasing emphasis of prominent pharmaceutical companies on HPAPIs, rising demand for antibody-drug conjugates, innovations in HPAPI manufacturing technologies, and emergent focus on precision medicine are some of the factors driving the growth of the global high potency APIs market.

Adroit Market Research report on global high potency APIs market gives a holistic view of the market from 2018 to 2028, which includes factors such as market drivers, restraints, opportunities and challenges. The market has been studied for historic years from 2018 to 2019, with the base year of estimation as 2020 and forecast from 2021 to 2028. The report covers the current status and future traits of the market at global as well as country level. In addition, the study also assesses the key players based on their product portfolio, geographic footprint, strategic initiatives and overall revenue. Prominent players operating in the global High Potency APIs market have been studied in detail.

HPAPIs are molecules that have very high cytotoxic properties, such as monoclonal antibody-drug conjugates, and thus require special containment facilities in order to protect operators from exposure. Approximately 60% of all oncology drugs are classified as highly potent. Capabilities to handle HPAPIs in dedicated suites are thus in strong demand (both for the API and drug product manufacturing stages) and the industry as a whole has been investing in containment capabilities to facilitate HPAPI production.

The global high potency APIs market is categorized based on product, manufacturers, drug type and application. On the basis of product, the HPAPIs is segmented into synthetic and biotech. The synthetic HPAPIs dominated the market with about 75% global market share, the use of biotech HPAPIs is steadily increasing as R&D on biological molecules for many therapies is gaining traction.

In 2020, North America was the largest market for high potency APIs owing to highly developed and regulated pharmaceutical industry. Cancer is the second leading cause of death, after cardiac diseases, in the North American region. Cancer therapy drugs have lion’s share in HPAPIs market, and show the strongest growth of any therapeutic category in the region’s pharmaceutical industry. Moreover, changing lifestyle and age related diseases is also fuelling HPAPIs market in this region. Key players of the global high potency APIs market include Pfizer Inc., Novartis International AG, Merck & Co., Teva Pharmaceutical Industries Ltd., Mylan, Inc., Boehringer Ingelheim, Sanofi, AbbVie, Eli Lilly and Company, AstraZeneca plc. among others.

Key segments of the global high potency APIs market

Product Overview, 2018-2028 (USD Billion)

• Synthetic
• Biotech

Manufacturers Overview, 2018-2028 (USD Billion)

• In-house
• Outsourced

Drug Type Overview, 2018-2028 (USD Billion)

• Innovative
• Generic

Application Overview, 2018-2028 (USD Billion)

• Oncology
• Hormonal
• Glaucoma
• Others

Regional Overview, 2018-2028 (USD Billion)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • United Kingdom
  • France
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of MEA